BURLINGTON, Mass. (AP) _ Flexion Therapeutics Inc. (FLXN) on Wednesday reported a loss of $41.5 million in its first quarter.
On a per-share basis, the Burlington, Massachusetts-based company said it had a loss of $1.09.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.13 per share.
The specialty pharmaceutical companies that specializes in pain relief posted revenue of $10.6 million in the period, which fell short of Street forecasts. Three analysts surveyed by Zacks expected $11.1 million.
Flexion Therapeutics expects full-year revenue in the range of $65 million to $80 million.
Flexion Therapeutics shares have fallen 14% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $9.68, a fall of 62% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FLXN at https://www.zacks.com/ap/FLXN